Adjuvant imatinib for GIST: duration likely matters
- PMID: 33524476
- DOI: 10.1016/j.annonc.2021.01.073
Adjuvant imatinib for GIST: duration likely matters
Conflict of interest statement
Disclosure ME is a consultant for Blueprint Medicines and has participated in advisory boards for Clinigen and Bayer. He is a trial physician in the Scandinavian Sarcoma Group, which receives trial support from Novartis. HJ has had a co-appointment at OrionPharma, has received fees from Neutron Therapeutics, and owns stocks of OrionPharma and Sartar Therapeutics. He is currently the Chair of the Scientific Advisory Board at OrionPharma and at Neutron Therapeutics Ltd.
Comment on
-
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆.Ann Oncol. 2021 Apr;32(4):533-541. doi: 10.1016/j.annonc.2021.01.004. Epub 2021 Jan 19. Ann Oncol. 2021. PMID: 33482247 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical